STI in HIV infection of `potential benefit'

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1275, 2001-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GIGHAART after STI: a new salvage therapy option in HIV infection?

By  

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Interleukin-2 as an Adjunct to Antiviral Therapy in HIV Infection

By Piscitelli S.C.  

Drug Safety, Vol. 22, Iss. 1, 2000-01 ,pp. : 19-31

Adis International

Access to resources Recommend Favorite

Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection

By Wyatt Christina M   Klotman Paul E  

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 275-287

Informa Healthcare

Access to resources Recommend Favorite

Bacterial Toxins: Potential Weapons Against HIV Infection

By  

Current Pharmaceutical Design, Vol. 11, Iss. 22, 2005-08 ,pp. : 2909-2926

Bentham Science Publishers

Access to resources Recommend Favorite

Cytokines in HIV-Infection - Inflammatory Damage or Therapeutic Potential?

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 8, Iss. 2, 2009-01 ,pp. : 115-130

Bentham Science Publishers

Access to resources Recommend Favorite